当前位置： SCI文献检索 > JOURNAL OF NEPHROLOGY期刊下所有文献 > Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?

Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?

Abstract：

:The partial correction of anemia and the normalization of phosphate and blood pressure are the mainstay of treatment of patients with chronic kidney disease (CKD). Available anti-hypertensive drugs, erythropoiesis stimulating agents (ESAs) and iron supplements have resolved quite satisfactorily the goal of controlling hypertension and partially correcting anemia. Unfortunately, the treatment of hyperphosphatemia is still far from resolved. Phosphate binders have poor tolerability and/or limited efficacy, leading to the prescription of many tablets that achieve only a mild-to-moderate effect. Moreover, increased consumption of tablets is associated with increased low tolerability, thus jeopardizing patient compliance and, in turn, the efficacy of phosphate binding. Compared to calcium-free binders, the cheaper calcium salts increase the risk of hypercalcemia, calciphylaxis and vascular calcification and possibly all-cause mortality. Calcium-free phosphate binders decrease serum phosphate levels without increasing the serum calcium concentration. The higher phosphate-binding efficacy of lanthanum carbonate compared to sevelamer should be balanced against its lack of pleiotropic effects on lipid metabolism and inflammation and the accumulation in bones. New iron-based phosphate binders are available. In addition to their phosphate binding capacity, they could also be useful to treat anemia. Iron citrate is seeking for such an indication because its iron absorption is significant. This could be of clinical importance, particularly in CKD patients not on dialysis, obviating the need for extra oral iron administration and possibly favoring compliance. In conclusion, the use of iron-based phosphate binders with significant iron absorption properties could represent a novel paradigm for correcting anemia and hyperphosphatemia in CKD patients.

journal_name

J Nephrol

journal_title

Journal of nephrology

authors

Locatelli F,Del Vecchio L

doi

10.1007/s40620-017-0421-y

subject

Has Abstract

pub_date

2017-12-01 00:00:00

pages

755-765

issue

eissn

1121-8428

issn

1724-6059

pii

10.1007/s40620-017-0421-y

journal_volume

pub_type

杂志文章,评审

在线工具

Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?